I can see where you’re coming from. However, we need to remember that until the reliability of a trial and the accuracy of its results have been considered by the scientific community, the quality of the data, and therefore the value of the drug to clinical medicine, has not been completely established.

Imagine if a company believed the results of a study were positive, published the details, and the share value rocketed. Then a few weeks later after presentation by the investigators at a congress, for some reason the scientific community does not accept the outcome (eg, owing to a flaw in its design that had been overlooked), and then the share value plummeted! 

I think we can discount the fact that  BOM had any serious flaws, given that (as I understand it) its design had the blessing of the FDA. So personally I have no concerns. But the general principle applies to all trials.